Vedana debuts with $46m to progress migraine therapies - Pharmaceutical Technology

Vedana’s clinical pipeline targets PACAP – an approach that has shown varying levels of success in migraine clinical trials thus far. Like Lundbeck’s bocunebart, Vedana’s clinical pipeline targets PACAP – an approach that has shown varying levels of success in clinical trials thus far. Vedana Therapeutics has emerged from stealth with $46m to push its migraine therapies further down the pipeline. Credit: helenreveur / Shutterstock.com. Vedana Therapeutics has emerged with $46m in hand from a Series A financing round, which will fund the Seattle-based biotech’s development efforts as it progresses its pipeline of next-generation migraine prevention therapies. Co-led by Canaan…

Source: Pharmaceutical Technology